Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.44 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22681258 | 0.80 | TSHR (0.40) | TSHRALDH1A1 | |
| SCHEMBL12607684 | 0.80 | POLB (0.41) | TSHRALDH1A1MAPK1KMT2AHDAC3 | |
| SCHEMBL12286077 | 0.79 | TSHR (0.38) | TSHRALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL21153559 | 0.78 | ALDH1A1 (0.39) | TSHRALDH1A1MAPK1 | |
| SCHEMBL17633835 | 0.78 | MEN1 (0.52) | TSHRALDH1A1KMT2A | |
| SCHEMBL23419312 | 0.77 | ALDH1A1 (0.48) | TSHRALDH1A1KMT2AHDAC3HDAC4 | |
| SCHEMBL22013330 | 0.77 | MAPK1 (0.44) | TSHRALDH1A1KDM4EMAPK1HIF1A | |
| SCHEMBL917149 | 0.75 | TSHR (0.71) | TSHRALDH1A1KDM4EMAPK1HIF1A | |
| SCHEMBL24244862 | 0.75 | TSHR (1.00) | TSHRALDH1A1KDM4EMAPK1HIF1A | |
| SCHEMBL12285924 | 0.75 | ZDHHC20 (0.47) | TSHRALDH1A1MAPK1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393937-A1 | STEROID COMPOUND AND CONJUGATE THEREOF | Duality Biologics (Suzhou) Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-3749670-B1 | 5-ALKYLTHIO-7-[(4-ARYLBENZYL)AMINO]-1(2)H-PYRAZOLO[4,3-D]PYRIMIDINES FOR TREATMENT OF LYMPHOMA | UNIV PALACKEHO (CZ) | 2021-10-06 | — | — | EP | disclosed |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180071404-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC (US) | 2018-03-15 | — | — | US | disclosed |
| US-9809590-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809590-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2953943-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-9598503-B2 | Methods and systems for polymer precipitation and generation of particles | CERULEAN PHARMA INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160002232-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130029909-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2013-01-31 | — | — | US | disclosed |
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120225825-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120114658-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. | 2012-05-10 | — | — | US | disclosed |
| US-20120064071-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20090258870-A1 | NOVEL ANSAMITOCIN DERIVATIVES | LEIBNIZ UNIVERSITAT HANNOVER (DE) | 2009-10-15 | — | — | US | disclosed |
| WO-2009124723-A2 | NOVEL AUREOTHIN DERIVATIVES | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE (DE) | 2009-10-15 | — | — | WO | disclosed |
| US-20080176958-A1 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | TSHR 4340/4885ALDH1A1 3011/4885KDM4E 4601/4885 |
| US-20120114658-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | TSHR 3647/4885ALDH1A1 1266/4885KDM4E 2821/4885 |
| US-20090258870-A1 | NOVEL ANSAMITOCIN DERIVATIVES | CGAS, FABP6, NISCH | TSHR 3629/4885ALDH1A1 820/4885KDM4E 3675/4885 |
| US-20120225825-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | TSHR 4340/4885ALDH1A1 3011/4885KDM4E 4601/4885 |
| US-20130029909-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | TSHR 3647/4885ALDH1A1 1266/4885KDM4E 2821/4885 |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | LTK, MUSK, FGFR1 | TSHR 177/4885ALDH1A1 2533/4885KDM4E 1420/4885 |
| US-20080176958-A1 | Cyclodextrin-based polymers for therapeutics delivery | CD47, SDCBP, BST2 | TSHR 3297/4885ALDH1A1 2837/4885KDM4E 3474/4885 |
| US-20120064071-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | TSHR 3647/4885ALDH1A1 1266/4885KDM4E 2821/4885 |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | TSHR 2636/4885ALDH1A1 2646/4885KDM4E 4388/4885 |
| US-20180071404-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | TSHR 3647/4885ALDH1A1 1266/4885KDM4E 2821/4885 |
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | AFF1, FLI1, F3 | TSHR 1035/4885ALDH1A1 1771/4885KDM4E 1410/4885 |
| US-20160002232-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | MUSK, TYRO3, IRAK3 | TSHR 524/4885ALDH1A1 1984/4885KDM4E 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.